Related Experiment Video
Updated: Jun 27, 2026
08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?
Mohammad Alsaeid1, Osamah Abu Hawi1, Talat Bessissow1
1Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada.
Journal of Clinical Medicine
|June 26, 2026
Summary
Managing inflammatory bowel diseases (IBD) with immune-mediated inflammatory diseases (IMIDs) and extraintestinal manifestations (EIM) requires a multidisciplinary approach. Early intervention and advanced therapies are crucial for patients with these complex conditions.
Area of Science:
- Gastroenterology
- Rheumatology
- Immunology
Background:
- Inflammatory bowel diseases (IBD) frequently co-occur with other immune-mediated inflammatory diseases (IMIDs) and extraintestinal manifestations (EIM).
- These comorbidities, including dermatological, ophthalmologic, musculoskeletal, and neurological issues, complicate patient management.
- The presence of IMIDs in IBD patients often indicates a poorer prognosis.
Purpose of the Study:
- To review and discuss optimal management and treatment strategies for IBD patients with associated IMIDs and EIM.
- To highlight the importance of a comprehensive approach in managing these complex cases.
Main Methods:
- A narrative review of published studies.
- Literature search conducted in PubMed up to December 31, 2025.
- Inclusion of systematic reviews, review articles, randomized trials, cohort studies, guidelines, and case series.
Main Results:
- Associated IMIDs in IBD are a poor prognostic factor, necessitating close monitoring and timely treatment escalation.
- Optimal therapeutic management involves a multidisciplinary strategy tailored to the severity of IBD, IMIDs, and EIM.
- Dual biologic therapies are emerging options for refractory, multi-organ disease.
Conclusions:
- Multidisciplinary collaboration among specialists is essential for effective IBD management with IMIDs/EIM.
- Aligning treatment goals and management plans across specialties is key to optimizing patient outcomes.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD: